Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Mariaelena Capone; Diana Giannarelli; Domenico Mallardo; Gabriele Madonna; Lucia Festino; Antonio Maria Grimaldi; Vito Vanella; Ester Simeone; Miriam Paone; Giuseppe Palmieri; Ernesta Cavalcanti; Corrado Caracò; Paolo Antonio Ascierto

doi:10.1186/s40425-018-0383-1

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

XML

Research Article

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Capone M, Giannarelli D, Mallardo D, et al

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Journal for ImmunoTherapy of Cancer 2018;6:74. doi: 10.1186/s40425-018-0383-1

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password